Cargando…
The success of opening single chronic total occlusion lesions to improve myocardialviabilitytrial (SOS-COMEDY): Study protocol of a prospective multicenter study
AIMS: Success of opening single (SOS)-comedy is a prospective multicenter study to compare the improvement in the decrease of myocardial viability by percutaneous coronary intervention (PCI) with that by optimal medical therapy (OMT) alone in patients with chronic total occlusion (CTO) of a single c...
Autores principales: | Huang, Rongchong, Song, Xiantao, Zhang, Haishan, Tian, Wen, Huang, Zheng, Zhang, Xingwei, Yang, Junqing, Zhang, Dongfeng, Wu, Jian, Zhong, Lei, Ting, Henry H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916680/ https://www.ncbi.nlm.nih.gov/pubmed/29668609 http://dx.doi.org/10.1097/MD.0000000000010443 |
Ejemplares similares
-
The success of opening concurrent chronic total occlusion lesion to improve cardiac function trial in patients with multi-vessel disease (SOS-moral): Study protocol of a prospective multicenter study
por: Tian, Jinfan, et al.
Publicado: (2020) -
Initial clinical experience of CrossBoss catheter for in-stent chronic total occlusion lesions: A case report
por: Zhao, Lei, et al.
Publicado: (2016) -
The Prognostic Effects of Ventricular Heart Rate Among Patients With Permanent Atrial Fibrillation With and Without Coronary Artery Disease: A Multicenter Prospective Observational Study
por: Wan, Huaibin, et al.
Publicado: (2015) -
The effect of Shexiang Tongxin Dropping Pills on coronary microvascular dysfunction (CMVD) among those with a mental disorder and non-obstructive coronary artery disease based on stress cardiac magnetic resonance images: A study protocol
por: Tian, Jinfan, et al.
Publicado: (2020) -
Effects of Shenxiang Suhe Pill on coronary heart disease complicated with nonalcoholic fatty liver disease: A case–control study
por: Ni, Jie, et al.
Publicado: (2022)